4D Molecular Therapeutics announced on September 18, 2024, that it highlighted robust and durable clinical activity for its lead product candidate, 4D-150, at its Wet AMD Development Day. The company presented positive interim data from the Phase 1/2 PRISM clinical trial, showcasing the potential of 4D-150 in treating wet age-related macular degeneration (wet AMD). This data supports the advancement of the therapy into late-stage development.
The company also detailed the design of its upcoming 4FRONT Phase 3 program for wet AMD. Management stated that it expects to initiate 4FRONT-1, the first of its 4D-150 Phase 3 studies in wet AMD, in the first quarter of 2025. This marks a crucial step towards potential regulatory approval and commercialization for the gene therapy.
The progress with 4D-150 is significant as it aims to address the high treatment burden associated with current wet AMD therapies, which often require frequent intravitreal injections. The positive interim data and the clear roadmap for Phase 3 development underscore the company's commitment to bringing a potentially paradigm-shifting treatment to patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.